These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 21819159)
1. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients. Elsner F; Zeppetella G; Porta-Sales J; Tagarro I Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159 [TBL] [Abstract][Full Text] [Related]
2. Opioids for the management of breakthrough pain in cancer patients. Zeppetella G; Davies AN Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465 [TBL] [Abstract][Full Text] [Related]
3. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176 [TBL] [Abstract][Full Text] [Related]
4. Evidence-based treatment of cancer-related breakthrough pain with opioids. Zeppetella G J Natl Compr Canc Netw; 2013 Mar; 11 Suppl 1():S37-43. PubMed ID: 23520185 [TBL] [Abstract][Full Text] [Related]
5. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Coluzzi PH; Schwartzberg L; Conroy JD; Charapata S; Gay M; Busch MA; Chavez J; Ashley J; Lebo D; McCracken M; Portenoy RK Pain; 2001 Mar; 91(1-2):123-30. PubMed ID: 11240084 [TBL] [Abstract][Full Text] [Related]
6. [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl]. Yomiya K; Kaneshima M; Kyosaka B; Warita E; Hosonuma R; Osato S Gan To Kagaku Ryoho; 2017 Apr; 44(4):289-293. PubMed ID: 28428506 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. Jandhyala R; Fullarton JR; Bennett MI J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337 [TBL] [Abstract][Full Text] [Related]
8. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. Farrar JT; Cleary J; Rauck R; Busch M; Nordbrock E J Natl Cancer Inst; 1998 Apr; 90(8):611-6. PubMed ID: 9554444 [TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F; Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417 [TBL] [Abstract][Full Text] [Related]
10. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients. Mercadante S Expert Opin Pharmacother; 2012 Apr; 13(6):873-8. PubMed ID: 22424558 [TBL] [Abstract][Full Text] [Related]
11. Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis. Jandhyala R; Fullarton J BMJ Support Palliat Care; 2012 Jun; 2(2):156-62. PubMed ID: 24654058 [TBL] [Abstract][Full Text] [Related]
12. Opioids for the management of breakthrough (episodic) pain in cancer patients. Zeppetella G; Ribeiro MD Cochrane Database Syst Rev; 2006 Jan; (1):CD004311. PubMed ID: 16437482 [TBL] [Abstract][Full Text] [Related]
13. Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics. Mystakidou K; Katsouda E; Parpa E; Vlahos L; Tsiatas ML Drug Deliv; 2006; 13(4):269-76. PubMed ID: 16766468 [TBL] [Abstract][Full Text] [Related]
14. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain]. Überall MA MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092 [TBL] [Abstract][Full Text] [Related]
15. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L J Opioid Manag; 2005; 1(1):36-40. PubMed ID: 17315410 [TBL] [Abstract][Full Text] [Related]
16. [Oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain]. Borgbjerg FM; Rosenberg J Ugeskr Laeger; 2000 Sep; 162(39):5237-40. PubMed ID: 11043058 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review. Rogríguez D; Urrutia G; Escobar Y; Moya J; Murillo M J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):228-46. PubMed ID: 26458018 [TBL] [Abstract][Full Text] [Related]
18. Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis. Shaiova L; Lapin J; Manco LS; Shasha D; Hu K; Harrison L; Portenoy RK Support Care Cancer; 2004 Apr; 12(4):268-73. PubMed ID: 14750002 [TBL] [Abstract][Full Text] [Related]